中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2010年
3期
134-138
,共5页
郭春霞%贺永文%彭程%雷延昌%翁志宏
郭春霞%賀永文%彭程%雷延昌%翁誌宏
곽춘하%하영문%팽정%뢰연창%옹지굉
商陆%抗病毒药(中药)%植物蛋白质类%肝炎病毒,乙型%疾病模型,动物%基因表达%DNA,病毒
商陸%抗病毒藥(中藥)%植物蛋白質類%肝炎病毒,乙型%疾病模型,動物%基因錶達%DNA,病毒
상륙%항병독약(중약)%식물단백질류%간염병독,을형%질병모형,동물%기인표체%DNA,병독
Phytolacca acinosa%Antiviral drugs(TCD)%Plant proteins%Hepatitis B virus%Disease models,animal%Gene expression%DNA,viral
目的 探讨商陆抗病毒蛋白(PAP)在急性HBV感染小鼠模型体内抗HBV的效果.方法 通过尾静脉注射具有复制能力的HBV真核表达质粒来建立小鼠急性HBV感染模型.根据注射后第1天小鼠血清HBsAg和HBeAg水平,从35只小鼠中选出24只进行配对,分为PAP治疗组(腹腔注射0.25 mg/kg PAP)和对照组.于PAP注射前、注射后第1、3、5、7天,时间分辨免疫荧光分析法检测小鼠血清HBsAg、HBeAg和抗-HBc水平,荧光定量PCR检测小鼠血清HBV DNA水平.注射后第7天HE染色检测肝组织病理变化,免疫组织化学检测肝组织HBsAg、HBeAg表达.采用配对t检验进行统计学分析.结果 与对照组相比,在PAP腹腔注射后第1、3、5天对HBsAg的抑制率分别为23%(t=116.3,P<0.05)、47%(t=38.2,P<0.05)、68%(t=23.7,P<0.05),对HBeAg的抑制率分别为36%(t=34.2,P<0.05)、55%(t=61.6,P<0.05)、83%(t=98.8,P<0.05),对HBV DNA的抑制率分别为70.7%(t=6.6,P<0.05)、86.9%(t=5.9,P<0.05)、95.2%(t=36.6,P<0.05)、95.3%(t=19.7,P<0.05).结论 0.25 mg/kg剂量的PAP在急性HBV感染小鼠模型体内对血清和肝组织的HBsAg、HBeAg的表达及HBV DNA的复制均有明显的抑制效果.
目的 探討商陸抗病毒蛋白(PAP)在急性HBV感染小鼠模型體內抗HBV的效果.方法 通過尾靜脈註射具有複製能力的HBV真覈錶達質粒來建立小鼠急性HBV感染模型.根據註射後第1天小鼠血清HBsAg和HBeAg水平,從35隻小鼠中選齣24隻進行配對,分為PAP治療組(腹腔註射0.25 mg/kg PAP)和對照組.于PAP註射前、註射後第1、3、5、7天,時間分辨免疫熒光分析法檢測小鼠血清HBsAg、HBeAg和抗-HBc水平,熒光定量PCR檢測小鼠血清HBV DNA水平.註射後第7天HE染色檢測肝組織病理變化,免疫組織化學檢測肝組織HBsAg、HBeAg錶達.採用配對t檢驗進行統計學分析.結果 與對照組相比,在PAP腹腔註射後第1、3、5天對HBsAg的抑製率分彆為23%(t=116.3,P<0.05)、47%(t=38.2,P<0.05)、68%(t=23.7,P<0.05),對HBeAg的抑製率分彆為36%(t=34.2,P<0.05)、55%(t=61.6,P<0.05)、83%(t=98.8,P<0.05),對HBV DNA的抑製率分彆為70.7%(t=6.6,P<0.05)、86.9%(t=5.9,P<0.05)、95.2%(t=36.6,P<0.05)、95.3%(t=19.7,P<0.05).結論 0.25 mg/kg劑量的PAP在急性HBV感染小鼠模型體內對血清和肝組織的HBsAg、HBeAg的錶達及HBV DNA的複製均有明顯的抑製效果.
목적 탐토상륙항병독단백(PAP)재급성HBV감염소서모형체내항HBV적효과.방법 통과미정맥주사구유복제능력적HBV진핵표체질립래건립소서급성HBV감염모형.근거주사후제1천소서혈청HBsAg화HBeAg수평,종35지소서중선출24지진행배대,분위PAP치료조(복강주사0.25 mg/kg PAP)화대조조.우PAP주사전、주사후제1、3、5、7천,시간분변면역형광분석법검측소서혈청HBsAg、HBeAg화항-HBc수평,형광정량PCR검측소서혈청HBV DNA수평.주사후제7천HE염색검측간조직병리변화,면역조직화학검측간조직HBsAg、HBeAg표체.채용배대t검험진행통계학분석.결과 여대조조상비,재PAP복강주사후제1、3、5천대HBsAg적억제솔분별위23%(t=116.3,P<0.05)、47%(t=38.2,P<0.05)、68%(t=23.7,P<0.05),대HBeAg적억제솔분별위36%(t=34.2,P<0.05)、55%(t=61.6,P<0.05)、83%(t=98.8,P<0.05),대HBV DNA적억제솔분별위70.7%(t=6.6,P<0.05)、86.9%(t=5.9,P<0.05)、95.2%(t=36.6,P<0.05)、95.3%(t=19.7,P<0.05).결론 0.25 mg/kg제량적PAP재급성HBV감염소서모형체내대혈청화간조직적HBsAg、HBeAg적표체급HBV DNA적복제균유명현적억제효과.
Objective To explore the antiviral effects of pokeweed antiviral protein (PAP) in mouse model of acute hepatitis B virus (HBV) infection. Methods Mouse model of acute HBV infection was established by hydrodynamictail vein injection with eukaryotic expression plasmid containing replicable HBV. Based on serum levels of hepatitis B surface antigen ( HBsAg) and hepatitis B e antigen ( HBeAg) at day 1 after injection, 24 mice were selected from 35 mice and averagely divided into PAP treated group (intraperitoneally injected with 0. 25 mg/kg PAP) and control group. Before injection and 1, 3, 5, 7 days after PAP injection, serum levels of HBsAg, HBeAg and anti-HBc were detected by enzyme-linked immunosorbent assay (ELISA). Serum level of HBV DNA was determined by fluorescence quantitative PCR (FQ-PCR). After 7 days of PAP injection, liver histopathological changes were examined using HE staining and expressions of HBsAg and HBeAg in the liver were assayed by immunohistochemical staining. The data were analyzed by paired t test. Results Compared with control group, the inhibition rates of HBsAg at dayl ,3,5 after PAP intraperitoneal injection were 23%, 47% and 68%, respectively (t=116. 3,t = 38. 2,t = 23. 7,all P<0.05), those of HBeAg were 36%, 55% and 83%, respectively (t=34. 2,t = 61. 6,t = 98. 9,all P<0. 05), those of HBV DNA were 70. 7%, 86.9%, 95.2% and 95.3%, respectively (t=6. 6, t=5. 9,t = 36. 6,t = 19. 7;all P<0. 05). Conclusion PAP with dose of 0. 25 mg/kg may significantly inhibit expressions of HBeAg and HBeAg and replication of HBV DNA in serum and liver tissues in acute HBV infected mice.
